Bill Dynan - NAR Cancer Editor
@nar-cancer-editor.bsky.social
Editor of fully Open Access journal publishing articles at the intersection of the nucleic acids research and cancer fields.
Reposted by Bill Dynan - NAR Cancer Editor
James Watson, Co-Discoverer of the Structure of DNA, Is Dead at 97 www.nytimes.com/2025/11/07/s...
James Watson, Co-Discoverer of the Structure of DNA, Is Dead at 97
www.nytimes.com
November 7, 2025 at 7:29 PM
James Watson, Co-Discoverer of the Structure of DNA, Is Dead at 97 www.nytimes.com/2025/11/07/s...
Excited to share: NAR Cancer Editor's Choice review article from Kyungjae Myung and colleagues provides a snapshot of the blossoming field of DNA damage response- and repair-targeted therapeutics. Focus is on small molecules currently in clnical trials. academic.oup.com/narcancer/ar...
November 7, 2025 at 6:57 PM
Excited to share: NAR Cancer Editor's Choice review article from Kyungjae Myung and colleagues provides a snapshot of the blossoming field of DNA damage response- and repair-targeted therapeutics. Focus is on small molecules currently in clnical trials. academic.oup.com/narcancer/ar...
Congratulations to Forment, O’Connor and coworkers on an Editors' Choice study in NAR Cancer, unraveling the mechanism by which addition of PARP inhibitors to AR pathway inhibitor therapy improves prostate cancer survival, even in the absence of HRR defects. academic.oup.com/narcancer/ar...
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
Abstract. Clinical trials show benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors
academic.oup.com
October 13, 2025 at 7:13 PM
Congratulations to Forment, O’Connor and coworkers on an Editors' Choice study in NAR Cancer, unraveling the mechanism by which addition of PARP inhibitors to AR pathway inhibitor therapy improves prostate cancer survival, even in the absence of HRR defects. academic.oup.com/narcancer/ar...
New in NAR Cancer: Loss of uL14 downregulates antigen processing and presentation components in melanoma cell lines - alters peptide pool available for presentation to create an escape mechanism from immune surveillance. From Anna Dopler and coworkers.
Here's the latest from the lab! In it we dive into the role of ribosomal proteins in antigen processing and presentation!
academic.oup.com/narcancer/ar...
academic.oup.com/narcancer/ar...
Loss of ribosomal protein uL14 enables tumor escape from T cell immunosurveillance
Abstract. The presentation of peptides on HLA molecules is essential to CD8+ T cell responses. Here, we show that loss of uL14 significantly downregulates
academic.oup.com
September 9, 2025 at 5:35 PM
New in NAR Cancer: Loss of uL14 downregulates antigen processing and presentation components in melanoma cell lines - alters peptide pool available for presentation to create an escape mechanism from immune surveillance. From Anna Dopler and coworkers.
Evaluation of 49 mRNA modification regulators across subtypes in human breast cancer reveals potential biomarkers and therapeutic targets. New in NAR Cancer, from Carlos Paula, Erik Dassi, Francesca Aguilo and coworkers at University of Trento and Umeå University. academic.oup.com/narcancer/ar...
Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort
Abstract. Epitranscriptomic modifications regulate gene expression and have been implicated in cancer, including breast cancer. Using the SCAN-B cohort, we
academic.oup.com
September 8, 2025 at 8:39 PM
Evaluation of 49 mRNA modification regulators across subtypes in human breast cancer reveals potential biomarkers and therapeutic targets. New in NAR Cancer, from Carlos Paula, Erik Dassi, Francesca Aguilo and coworkers at University of Trento and Umeå University. academic.oup.com/narcancer/ar...
We described Ku-RNA binding in 1998, but had to wait 27 years for Zha and coworkers to discover the significance. A lesson in patience. 2/2 pubs.acs.org/doi/10.1021/...
Characterization of the RNA Binding Properties of Ku Protein†
Ku protein, a heterodimer of 70 and 83 kDa polypeptides, is the regulatory component of the DNA-dependent protein kinase (DNA-PK). Ku protein binds to DNA ends and is essential for DNA double-strand b...
pubs.acs.org
August 19, 2025 at 3:33 PM
We described Ku-RNA binding in 1998, but had to wait 27 years for Zha and coworkers to discover the significance. A lesson in patience. 2/2 pubs.acs.org/doi/10.1021/...
Congrats to our Editorial Board member Shan Zha for amazing study attributing essentiality of Ku protein in primates to modulation of RNA-driven innate immunity. 1/2 www.nature.com/articles/s41...
Ku limits RNA-induced innate immunity to allow Alu expansion in primates - Nature
Studies on the essentiality of Ku in human cells reveal that Ku interacts with diverse double-stranded RNA molecules, including antisense Alu, and enables tolerance of Alu sequence expansion in p...
www.nature.com
August 19, 2025 at 3:28 PM
Congrats to our Editorial Board member Shan Zha for amazing study attributing essentiality of Ku protein in primates to modulation of RNA-driven innate immunity. 1/2 www.nature.com/articles/s41...
N6-methyladenosine in R-loop homeostasis. Short review in NAR Cancer from Chun-Long Chen and coworkers. Effects on transcription, repair, centromere and telomere stability, and R-loop dynamics. Targeting as a cancer therapeutic strategy. academic.oup.com/narcancer/ar...
m6A modification in R-loop homeostasis: a potential target for cancer therapeutics
Abstract. R-loops or DNA–RNA hybrids are prominent nucleic acid structures that commonly arise during transcription. These structures play important biolog
academic.oup.com
August 15, 2025 at 4:14 PM
N6-methyladenosine in R-loop homeostasis. Short review in NAR Cancer from Chun-Long Chen and coworkers. Effects on transcription, repair, centromere and telomere stability, and R-loop dynamics. Targeting as a cancer therapeutic strategy. academic.oup.com/narcancer/ar...
Beyond BRCA status: machine-learning assisted multichannel imaging platform for cell-by-cell analysis of HR competency, enabling patient stratification. “Editor’s Choice” in NAR Cancer. academic.oup.com/narcancer/ar...
Automated machine learning profiling with MAP-HR for quantifying homologous recombination foci in patient samples
Abstract. Accurate visualization and quantification of homologous recombination (HR)-associated foci in readily available patient samples are critical for
academic.oup.com
August 14, 2025 at 5:34 PM
Beyond BRCA status: machine-learning assisted multichannel imaging platform for cell-by-cell analysis of HR competency, enabling patient stratification. “Editor’s Choice” in NAR Cancer. academic.oup.com/narcancer/ar...
New insights into gene regulation in melanoma, the deadliest skin cancer: SETD6-catalyzed methylation of BRD4 and chromatin-localized interaction with MITF. From Tzofit Elbaz Biton, Dan Levy, and coworkers, published in NAR Cancer. academic.oup.com/narcancer/ar...
SETD6 mediates selective interaction and genomic occupancy of BRD4 and MITF in melanoma cells
Abstract. Aberrant transcriptional programs mediate malignant transformation of melanoma, the most aggressive form of skin cancer. The lysine methyltransfe
academic.oup.com
August 10, 2025 at 7:29 PM
New insights into gene regulation in melanoma, the deadliest skin cancer: SETD6-catalyzed methylation of BRD4 and chromatin-localized interaction with MITF. From Tzofit Elbaz Biton, Dan Levy, and coworkers, published in NAR Cancer. academic.oup.com/narcancer/ar...
Our sister journal, Nucleic Acids Research, has opened a search for an Executive Editor. Great opportunity for mid-career or senior investigator looking to be part of a great team, handle 100-150 papers per year, and attend the annual EE meeting. Details at: academic.oup.com/nar/pages/ex...
NAR seeks a new Executive Editor
Overview of the Journal
Nucleic Acids Research (NAR) is a leading open access molecular biology journal published by Oxford University Press. It provides rapid
academic.oup.com
August 5, 2025 at 5:46 PM
Our sister journal, Nucleic Acids Research, has opened a search for an Executive Editor. Great opportunity for mid-career or senior investigator looking to be part of a great team, handle 100-150 papers per year, and attend the annual EE meeting. Details at: academic.oup.com/nar/pages/ex...
Are key cancer driver mutations amenable to editing by endogenous ADAR enzymes? The scope of correctable mutations is charted for the first time in an Editor's Choice paper, newly published in NAR Cancer. From Rona Merdler-Rabinowicz and colleagues. academic.oup.com/narcancer/ar...
A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment
Abstract. Adenosine deaminases acting on RNA (ADAR) enzymes constitute a natural cellular mechanism that induces A-to-I(G) editing, introducing genetic cha
academic.oup.com
May 12, 2025 at 3:08 PM
Are key cancer driver mutations amenable to editing by endogenous ADAR enzymes? The scope of correctable mutations is charted for the first time in an Editor's Choice paper, newly published in NAR Cancer. From Rona Merdler-Rabinowicz and colleagues. academic.oup.com/narcancer/ar...
New in NAR Cancer. A critical examination of mutations in conserved m6A motifs: low recurrence and maybe not a primary mechanism for altering gene function. From Luis A. Diaz and coworkers, @mskcancercenter.bsky.social academic.oup.com/narcancer/ar...
April 26, 2025 at 4:43 PM
New in NAR Cancer. A critical examination of mutations in conserved m6A motifs: low recurrence and maybe not a primary mechanism for altering gene function. From Luis A. Diaz and coworkers, @mskcancercenter.bsky.social academic.oup.com/narcancer/ar...
Watch the replay of Elise Fouquerel and Rob Sobol's talks at today's NAR Cancer 5th anniversary symposium (offered in collaboration with Social DNAing). Special thanks to guest host Li Lan. Link to video at the Social DNAing website: www.cancer.columbia.edu/research/pro...
Social DNAing
Social DNAing Webinar Series, sponsored by the Cancer Genomics and Epigenomics Program at Columbia University, aims to provide a virtual meeting room for the genomic instability community worldwide.
www.cancer.columbia.edu
April 18, 2025 at 2:01 AM
Watch the replay of Elise Fouquerel and Rob Sobol's talks at today's NAR Cancer 5th anniversary symposium (offered in collaboration with Social DNAing). Special thanks to guest host Li Lan. Link to video at the Social DNAing website: www.cancer.columbia.edu/research/pro...
NAR Cancer 5th anniversary symposium on manipulating DNA repair and DDR for cancer therapy - 4th and final session, Thursday April 17, noon Eastern. Elise Fouquerel and Rob Sobol on emerging targets. Link to free registration: academic.oup.com/narcancer/pa...
April 15, 2025 at 11:40 AM
NAR Cancer 5th anniversary symposium on manipulating DNA repair and DDR for cancer therapy - 4th and final session, Thursday April 17, noon Eastern. Elise Fouquerel and Rob Sobol on emerging targets. Link to free registration: academic.oup.com/narcancer/pa...
Replay of two great talks from last week's NAR Cancer 5th anniversary symposium on manipulating the DNA damage response. Dale Ramsden on DNA polymerase theta - what it repairs and when, and Katie Pawelczak on a first-in-class RPA inhibitor. Find the link at www.cancer.columbia.edu/research/pro...
Social DNAing
Social DNAing Webinar Series, sponsored by the Cancer Genomics and Epigenomics Program at Columbia University, aims to provide a virtual meeting room for the genomic instability community worldwide.
www.cancer.columbia.edu
March 17, 2025 at 12:53 AM
Replay of two great talks from last week's NAR Cancer 5th anniversary symposium on manipulating the DNA damage response. Dale Ramsden on DNA polymerase theta - what it repairs and when, and Katie Pawelczak on a first-in-class RPA inhibitor. Find the link at www.cancer.columbia.edu/research/pro...
NAR Cancer 5th Anniversary symposium in cooperation with Social DNAing: Thursday, March 13, noon US Eastern. Dale Ramsden on Pol theta and Katie Pawelczak on targeting RPA.
Program info and link to register: academic.oup.com/narcancer/pa...
Program info and link to register: academic.oup.com/narcancer/pa...
March 10, 2025 at 6:55 PM
NAR Cancer 5th Anniversary symposium in cooperation with Social DNAing: Thursday, March 13, noon US Eastern. Dale Ramsden on Pol theta and Katie Pawelczak on targeting RPA.
Program info and link to register: academic.oup.com/narcancer/pa...
Program info and link to register: academic.oup.com/narcancer/pa...
Novel approach for simultaneous profiling of long-range genetic and epigenetic changes in matched cancer samples, focusing on clear cell renal cell carcinoma. New in NAR Cancer. From Sapir Margalit, Yuval Ebenstein, and others, Tel Aviv University. academic.oup.com/narcancer/ar...
Optical genome and epigenome mapping of clear cell renal cell carcinoma
Abstract. Cancer cells display complex genomic aberrations that include large-scale genetic rearrangements and epigenetic modulation that are not easily ca
academic.oup.com
March 10, 2025 at 6:35 PM
Novel approach for simultaneous profiling of long-range genetic and epigenetic changes in matched cancer samples, focusing on clear cell renal cell carcinoma. New in NAR Cancer. From Sapir Margalit, Yuval Ebenstein, and others, Tel Aviv University. academic.oup.com/narcancer/ar...
New Cancer Grand Challenges announced: mechanisms driving unassigned mutational signatures, the dark proteome, and more: www.cancergrandchallenges.org/new-challeng...
New challenges
Explore the challenges currently open for Expressions of Interest.
www.cancergrandchallenges.org
March 5, 2025 at 6:48 PM
New Cancer Grand Challenges announced: mechanisms driving unassigned mutational signatures, the dark proteome, and more: www.cancergrandchallenges.org/new-challeng...
Reaching out to #earlycareerinvestigators @narjournal.bsky.social
🌟 Thrilled to welcome our new Early Career Investigators to NAR including Marta Montes (@mmontesr.bsky.social), a Principal investigator of the RNA and Senescence group at the University of Navarra! 🧬
#NucleicAcidsResearch #MolecularBiology #EarlyCareerInvestigators
#Mentorship #OpenAccessResearch
#NucleicAcidsResearch #MolecularBiology #EarlyCareerInvestigators
#Mentorship #OpenAccessResearch
March 5, 2025 at 2:57 PM
Reaching out to #earlycareerinvestigators @narjournal.bsky.social
First in vivo DNA aptamer selection using an orthotopic patient-derived xenograft glioblastoma mouse model to identify tumor-homing DNA aptamers. From Caroline Doherty, LJ Maher and colleagues at Mayo Clinic. New in NAR Cancer. academic.oup.com/narcancer/ar...
In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model
Abstract. Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor of adults. Current therapeutic options yield dismal prognoses
academic.oup.com
February 27, 2025 at 2:12 PM
First in vivo DNA aptamer selection using an orthotopic patient-derived xenograft glioblastoma mouse model to identify tumor-homing DNA aptamers. From Caroline Doherty, LJ Maher and colleagues at Mayo Clinic. New in NAR Cancer. academic.oup.com/narcancer/ar...
New in NAR Cancer - Use of human artificial chromosome (HAC)-based assay to analyze chromosomal instability in IDH-mutant gliomas suggests a precision medicine approach to improve therapeutic outcomes - from Goncharov and coworkers. academic.oup.com/narcancer/ar...
Therapy enhancing chromosome instability may be advantageous for IDH1R132H/WT gliomas
Abstract. Recently revised brain tumor classification suggested a glioma treatment strategy that takes into consideration molecular variants in IDH1 and TP
academic.oup.com
February 22, 2025 at 8:52 PM
New in NAR Cancer - Use of human artificial chromosome (HAC)-based assay to analyze chromosomal instability in IDH-mutant gliomas suggests a precision medicine approach to improve therapeutic outcomes - from Goncharov and coworkers. academic.oup.com/narcancer/ar...
In NAR Cancer: Loss of powerful G4 resolvase FANCJ sensitizes to G4-stabilizing ligand - shown in cancer cells and in C. elegans in vivo. Proof-of-principle for synthetic lethality-based therapeutic approach. Marcello Germoglio et al, IBBC and University of Naples. academic.oup.com/narcancer/ar...
February 14, 2025 at 7:14 PM
In NAR Cancer: Loss of powerful G4 resolvase FANCJ sensitizes to G4-stabilizing ligand - shown in cancer cells and in C. elegans in vivo. Proof-of-principle for synthetic lethality-based therapeutic approach. Marcello Germoglio et al, IBBC and University of Naples. academic.oup.com/narcancer/ar...
Watch the replay - terrific and well attended talks from Kara Bernstein (RAD51 paralogs) and Joanna Loizou (pol theta) yesterday at the NAR Cancer 5th anniversary symposium. Link to "watch the latest replay" at www.cancer.columbia.edu/research/pro...
February 14, 2025 at 6:52 PM
Watch the replay - terrific and well attended talks from Kara Bernstein (RAD51 paralogs) and Joanna Loizou (pol theta) yesterday at the NAR Cancer 5th anniversary symposium. Link to "watch the latest replay" at www.cancer.columbia.edu/research/pro...
This is terrific to see! Proud graduate student Dory Fawwal presents her new NAR Cancer paper to her peers and colleagues. Oncohistone H3E50K. academic.oup.com/narcancer/ar...
February 14, 2025 at 5:15 PM
This is terrific to see! Proud graduate student Dory Fawwal presents her new NAR Cancer paper to her peers and colleagues. Oncohistone H3E50K. academic.oup.com/narcancer/ar...